CARDIFF ONCOLOGY, INC. Share-based Payment Arrangement, Plan Modification, Incremental Cost
CARDIFF ONCOLOGY, INC. (CRDF) reported Share-based Payment Arrangement, Plan Modification, Incremental Cost of $600.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost · last filed 2025-02-27
- CARDIFF ONCOLOGY, INC. share-based payment arrangement, plan modification, incremental cost for the quarter ending 2023-09-30 was $600.00K.
- CARDIFF ONCOLOGY, INC. share-based payment arrangement, plan modification, incremental cost for the quarter ending 2023-06-30 was $600.00K.
- CARDIFF ONCOLOGY, INC. share-based payment arrangement, plan modification, incremental cost for fiscal 2024 was $600.00K, a 0.00% change from fiscal 2023.
- CARDIFF ONCOLOGY, INC. share-based payment arrangement, plan modification, incremental cost for fiscal 2023 was $600.00K.
| Period end | Share-based Payment Arrangement, Plan Modification, Incremental Cost 3 month | Share-based Payment Arrangement, Plan Modification, Incremental Cost 6 month | Share-based Payment Arrangement, Plan Modification, Incremental Cost 12 month |
|---|---|---|---|
| 2024-12-31 | $600.00K 10-K · filed 2025-02-27 | ||
| 2023-12-31 | $600.00K 10-K · filed 2024-02-29 | ||
| 2023-09-30 | $600.00K 10-Q · filed 2023-11-02 | $1.20M derived: sum of 2 quarters · filed 2023-11-02 | |
| 2023-06-30 | $600.00K 10-Q · filed 2023-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B |